Menu
Bio-Rad Laboratories, Inc. is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, its products advance the discovery process and improve healthcare. Bio-Rad's customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020.
1000 Alfred Nobel Dr
Hercules, California 94547-1811
Phone: 15107247000
www.bio-rad.com
Bio-Rad Laboratories (BIO) has issued an update. Simon May, a key executive at Bio-Rad Laboratories, has announced his resignation to take on a new…
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global Manufacturing, to the position of Executive Vice President and President of the Life Science Group, effective May 1, 2024. He succeeds Dr. Simon May, who has announced his decision Jetzt den vollständigen Artikel lesen
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 800-274-8461 Jetzt den vollständigen Artikel lesen
Oncocyte (OCX) shares rallied 90% in post-market after the company announced a partnership with Bio-Rad (BIO) for the global launch of its GraftAssure assay. Read more here.
Oncocyte (OCX) announces a partnership with Bio-Rad Laboratories (BIO) for the commercialization of GraftAssure™ assay, powered by Droplet Digital PCR. The agreement grants Bio-Rad global exclusivity in transplant monitoring commercialization, with an equity investment option upon FDA clearance. The new product is set to launch in Q2 2024 in the US and EU.
Bio-Rad Laboratories (BIO) has shared an update. Dr. Andrew Last, Executive Vice President and Chief Operating Officer of Bio-Rad Laboratories, pla…
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of Bio-Rad’s executive leadership team to ensure a smooth transition while the company conducts a search Jetzt den vollständigen Artikel lesen
Bio-Rad Laboratories (BIO) just unveiled an update. Bio-Rad Laboratories, Inc. has appointed Roop K. Lakkaraju as their new Executive Vice Presiden…
